$4.42
2.55% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US02157Q1094
Symbol
ANRO
Sector
Industry

Alto Neuroscience Stock price

$4.42
+0.05 1.14% 1M
-8.50 65.79% 6M
-11.58 72.38% YTD
-11.58 72.38% 1Y
-11.58 72.38% 3Y
-11.58 72.38% 5Y
-11.58 72.38% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.11 2.55%
ISIN
US02157Q1094
Symbol
ANRO
Sector
Industry

Key metrics

Market capitalization $119.16m
Enterprise Value $-45.75m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 0.72
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-63.38m
Cash position $181.70m
EPS (TTM) EPS $-2.13
P/E forward negative
Short interest 14.42%
Show more

Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Alto Neuroscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Alto Neuroscience forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Alto Neuroscience forecast:

Buy
71%
Hold
29%

Financial data from Alto Neuroscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.49 0.49
-
-
-0.49 -0.49
-
-
- Selling and Administrative Expenses 17 17
-
-
- Research and Development Expense 46 46
-
-
-63 -63
-
-
- Depreciation and Amortization 0.49 0.49
-
-
EBIT (Operating Income) EBIT -63 -63
-
-
Net Profit -57 -57
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alto Neuroscience Stock News

Neutral
Business Wire
14 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. “We have sharpened our cl...
Neutral
Business Wire
22 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in November: Stifel 2024 Healthcare Conference, ...
Neutral
Business Wire
about one month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montg...
More Alto Neuroscience News

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Head office United States
CEO Amit Etkin
Employees 63
Founded 2019
Website www.altoneuroscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today